Navigation Links
UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
Date:9/4/2007

Charlottesville, Va., September 4, 2007 A University of Virginia researcher has been awarded a $3.6 million grant from the National Institute of Allergy and Infectious Diseases to combat a growing international health crisis.

Dr. Richard Guerrant, founder of UVas Center for Global Health, plans to take a unique approach to treating the bacterium Clostridium difficile, which is growing increasingly resistant to certain antibiotics that work against bacteria of the colon. Clostridium difficile (C. diff) is a bacterium that causes diarrhea and can lead to more serious intestinal conditions such as colitis.

This is a huge problem which has been getting worse since the mid-1980s. Previously healthy young people are becoming ill with the disease and the national mortality rate from the disease has more than doubled in the last few years, Guerrant says.

Patients who are most at risk from C. diff have traditionally been older or have taken antibiotics for an extended period of time. The antibiotics eradicate the beneficial bacteria which all people have in their digestive tract, leaving the drug resistant C. diff to flourish. An estimated 5 to 7 percent of residents of assisted living and nursing facilities are infected with the bacterium.

The Centers for Disease Control reports there have been C. diff outbreaks in hospitals in 23 states. The drug-resistant strain has been blamed for more than 100 deaths over an 18-month period at a hospital in Quebec. The bacteria are found in feces. Infection can occur when people touch items or surfaces contaminated with feces.

C. difficile produces two toxins which cause the body to react with diarrhea, fever, loss of appetite, nausea and abdominal pain. Because the bacterium is proving resistant to antibiotics, Guerrant proposes countering the effects of the toxins instead of targeting the bacterium.

The current treatments have been to try a new antibiotic on the bacterium, which kills even more of the beneficial bacteria and allows C. diff to continue ravaging the patients, Guerrant says. By rendering the toxins harmless, we hope we can keep the debilitating effects of C. diff from proving fatal.

Guerrant says pilot data show this approach has great promise and he plans to collaborate with other UVa scientists and a pharmaceutical company to develop the treatment.


'/>"/>

Contact: David Foreman
davidforeman@virginia.edu
434-924-2242
University of Virginia Health System
Source:Eurekalert

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
4. New Hair in 15 Days Could Now Be A Possibility Say Researchers
5. Researchers at Cornell University as been reported using research fund by false claims
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. Gene researchers make Malaria-resistant mosquito
9. Researchers developed world’s smallest toothbrus
10. Researchers discover receptor cells that can cause epilepsy
11. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a definitive agreement ... laboratory service centers across the country. Launched in April of 2015, Apifiny is the ... prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast ... developing novel, clinical-stage therapies for sickle cell disease and ... public offering of 29,090,910 units at a price to ... of one share of the Company,s common stock and ... common stock at an exercise price of $0.42 per ...
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
Breaking Medicine Technology: